OneCyte and Kemp Proteins have announced a collaboration that integrates single-cell technology with artificial intelligence to enhance cell line development for biopharmaceutical manufacturing. The partnership combines OneCyte's proprietary single-cell platform with Kemp Proteins' machine learning-driven PROTiQ platform to accelerate clone selection processes.
The collaboration leverages OneCyte's single-cell technology, which enables high-throughput and high-speed clone selection capabilities. This technology is paired with Kemp Proteins' molecular engineering expertise and its PROTiQ platform, which uses machine learning algorithms to optimize protein development workflows.